Xencor, Inc. (XNCR) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10, Morningstar.com reports. The firm had revenue of $13.34 million for the quarter, compared to the consensus estimate of $8.15 million. Xencor had a net margin of 18.19% and a return on equity of 5.98%.
Shares of Xencor (XNCR) traded up 5.00% during mid-day trading on Tuesday, reaching $23.33. 47,171 shares of the company’s stock were exchanged. The stock has a market capitalization of $1.09 billion, a PE ratio of 66.09 and a beta of 2.14. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38. The company’s 50 day moving average is $22.34 and its 200 day moving average is $23.09.
Several analysts have recently commented on XNCR shares. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Wedbush restated an “outperform” rating and set a $29.00 price objective on shares of Xencor in a research report on Wednesday, May 10th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $28.67.
In related news, major shareholder John S. Stafford III acquired 1,500 shares of Xencor stock in a transaction on Friday, June 16th. The stock was bought at an average cost of $19.67 per share, for a total transaction of $29,505.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III acquired 6,000 shares of Xencor stock in a transaction on Wednesday, June 28th. The shares were bought at an average price of $19.94 per share, with a total value of $119,640.00. The disclosure for this purchase can be found here. Insiders have sold 34,766 shares of company stock valued at $739,408 over the last 90 days. 4.14% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of XNCR. Redmile Group LLC boosted its position in Xencor by 59.9% in the first quarter. Redmile Group LLC now owns 1,592,526 shares of the biopharmaceutical company’s stock worth $38,093,000 after buying an additional 596,426 shares in the last quarter. Norges Bank bought a new position in Xencor during the fourth quarter worth $15,601,000. State Street Corp boosted its position in Xencor by 17.5% in the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock worth $23,751,000 after buying an additional 148,136 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Xencor by 254.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 182,256 shares of the biopharmaceutical company’s stock worth $4,797,000 after buying an additional 130,778 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in Xencor by 54.5% in the first quarter. Acadian Asset Management LLC now owns 322,768 shares of the biopharmaceutical company’s stock worth $7,722,000 after buying an additional 113,862 shares in the last quarter. Institutional investors own 74.12% of the company’s stock.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.